NAMS Releases Its 2017 Hormone Therapy Position Statement

Posted on June 20, 2017

Read Story

Source: The North American Menopause Society

June 2017 -- “Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture,” says Dr. JoAnn V. Pinkerton, NAMS Executive Director and Chair of the Position Statement Advisory Panel. “NAMS discovered through its review of the literature published since the 2012 Position Statement that its previous position that hormone therapy should be prescribed only for the ‘lowest dose for the shortest period of time’ may be inadequate or even harmful for some women. NAMS has clarified this position to the more fitting concept of the ‘appropriate dose, duration, regimen, and route of administration’ that provides the most benefit with the minimal amount of risk.”